A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients

Exclusion Criteria

• •1. Known uncontrolled or symptomatic central nervous system metastatic disease.
• •2. Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade \>1 (National Cancer Institute Common terminology Criteria \[NCI CTCAE\] v.5.0).
• •3. Inadequate organ or bone marrow function.
• •4. Pregnant or breast-feeding woman.
• •5. Known allergies, hypersensitivity, or intolerance to SSGJ-707. The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.